PUBLISHER: TechNavio | PRODUCT CODE: 1080286
PUBLISHER: TechNavio | PRODUCT CODE: 1080286
Technavio has been monitoring the zika virus therapeutics market and it is poised to grow by $ 4.97 billion during 2022-2026, accelerating at a CAGR of 5.25% during the forecast period. Our report on the zika virus therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the availability of serology kit for qualitative diagnosis of zika virus infection, high incidence rate of infection, and disease burden of zika virus infection and associated comorbidities.
The zika virus therapeutics market analysis includes the product segment and geographic landscape.
Technavio's zika virus therapeutics market is segmented as below:
By Product
By Geographical Landscape
This study identifies the increasing efforts by government and private organizations to facilitate vaccine development as one of the prime reasons driving the zika virus therapeutics market growth during the next few years. Also, classification of zika virus infection as a public health emergency and novel approach for vaccine development will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on zika virus therapeutics market covers the following areas:
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading zika virus therapeutics market vendors that include Johnson and Johnson, Aurobindo Pharma Ltd., Granules India Ltd., Perrigo Co. Plc, Sun Pharmaceutical Industries Ltd., Bharat Biotech Ltd., Emergent BioSolutions Inc., Takeda Pharmaceutical Co. Ltd., GeoVax Labs Inc., IMV Inc., Inovio Pharmaceuticals Inc., Moderna Inc., Merck and Co. Inc., and Valneva SE. Also, the zika virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Exhibits: